Get the Stockscreener App
181.35
0.14%
0.25
After Hours:
181.35
Overview
News
Price History
Option Chain
Financials
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $181.35, with a volume of 2.83M.
It is up +0.14% in the last 24 hours and up +12.01% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$181.10
Open:
$181.46
24h Volume:
2.83M
Relative Volume:
0.63
Market Cap:
$128.35B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
35.05
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
-3.75%
1M Performance:
+12.01%
6M Performance:
-19.29%
1Y Performance:
-9.83%
1-Day Range:
$180.50
$183.55
1-Week Range:
$177.93
$188.18
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher’s Cepheid Ebola Tests Highlight Diagnostics Role In Global Crises - Yahoo Finance
Masimo CEO stepping down following acquisition by Danaher - Modern Healthcare
Danaher Corporation’s (DHR) Recovery Fell Short of Investor Expectations - Yahoo Finance UK
Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts - Insider Monkey
Danaher Corp. Stock (US2358511028): Diagnostics expansion keeps diversified healthcare group in focu - AD HOC NEWS
Danaher boosts product portfolio with the acquisition of Masimo - MSN
Danaher Deepens Diagnostics Reach As Masimo Deal Reshapes Healthcare Focus - Yahoo Finance
Danaher completes acquisition of Masimo, company delists from Nasdaq By Investing.com - Investing.com Nigeria
Danaher Corp. Stock (US2358511028): shares in focus after quiet trading week - AD HOC NEWS
Is Danaher stock underperforming the S&P 500? - MSN
Danaher Masimo Deal Strengthens S&P 500 Healthcare Growth Story - Kalkine Media
Masimo (MASI) director equity cashed out at $180 per share in Danaher merger - Stock Titan
Masimo (MASI) EVP equity cashed out and converted in Danaher merger - Stock Titan
Masimo (MASI) CCO reports merger-driven cancellation and conversion of equity awards - Stock Titan
Masimo (MASI) CHRO equity canceled, cashed out and rolled into Danaher - Stock Titan
Masimo (MASI) GC reports RSU disposals as Danaher merger converts awards - Stock Titan
Masimo (MASI) CMO disposes RSUs, options as Danaher merger closes - Stock Titan
Masimo (MASI) CFO exits company stock as Danaher cash merger closes - Stock Titan
Masimo (MASI) CEO awards canceled, paid $180 per share in Danaher deal - Stock Titan
Deals tracker: Medtronic buys Scientia Vascular for $550M - Modern Healthcare
3 Reasons to Avoid DHR and 1 Stock to Buy Instead - Yahoo Finance
Danaher Boosts Product Portfolio With the Acquisition of Masimo - TradingView
Implied Volatility Surging for Danaher Stock Options - Yahoo Finance UK
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
DHR Initiated Coverage On by Piper Sandler -- Price Target Annou - GuruFocus
1 Unstoppable Healthcare Cash Cow to Buy Hand Over Fist and Hold for 25 Years - Yahoo Finance
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Strong Performance Continues at DHR's Biotechnology Unit: What's Next? - Yahoo Finance
Is Now The Time To Look At Buying Danaher Corporation (NYSE:DHR)? - Yahoo Finance
Danaher Closes $9.9B Acquisition of Masimo - Medical Product Outsourcing
Piper Sandler initiates Danaher stock coverage with neutral rating By Investing.com - Investing.com Canada
Piper Sandler initiates Danaher stock coverage with neutral rating - Investing.com
Danaher closes $9.9B Masimo buyout - Yahoo Finance
Why Is Danaher Drawing Attention Among Bluestock Indices Trends? - Kalkine Media
Danaher Closes on Acquisition of Masimo - Orange County Business Journal
Danaher Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Danaher completes acquisition of Masimo, company delists from Nasdaq - Investing.com UK
Danaher (DHR) Completes Acquisition of Masimo, Expanding Diagnos - GuruFocus
Danaher Completes Acquisition of Masimo, Expanding Acute Care Diagnostics Platform - citybiz
Danaher completes $10B acquisition of Masimo - MassDevice
Masimo Pays Off and Terminates 2025 Credit Agreement as Danaher Merger Closes - TradingView
Danaher acquires Masimo (MASI) in all-cash $180-per-share takeover and delisting - Stock Titan
Danaher completes acquisition of Masimo Corporation - Investing.com
Danaher completes acquisition of Masimo Corporation By Investing.com - Investing.com Canada
Danaher Completes Acquisition of Masimo Corporation - Yahoo Finance
Danaher Corporation $DHR Shares Sold by Motley Fool Wealth Management LLC - MarketBeat
Danaher Corporation $DHR Shares Acquired by Cerity Partners LLC - MarketBeat
Danaher Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Wolfe Research Downgrades Danaher Corporation (DHR) - Insider Monkey
Clearbridge Investments LLC Trims Stock Holdings in Danaher Corporation $DHR - MarketBeat
Danaher (DHR) Moves Towards Acquisition of Masimo (MASI) - GuruFocus
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):